

EFFICACY OF AN INNOVATIVE CREAM ON BIOMARKERS FOR AGING IN MATURE, FRAGILE SKIN


Glynis Ablon, MD¹; Todd Schlesinger MD²; Alan Widgerow, MBBCh, MMed, FCS, FACS³; Sindhu Garimella MS³; Thu Q. Nguyen, PhD³; Christine Emesiani, PharmD³; Matthew Meckfessel, PhD³

¹Associate Clinical Professor, UCLA, Founder Ablon Skin Institute & Research Center; ²Clinical Research Center of the Carolinas, The George Washington University School of Medicine and Health Sciences; ³Galderma Laboratories, L.P., Fort Worth, TX

BACKGROUND

- This study evaluated the efficacy and safety of an innovative cream ([GC] Galderma Laboratories, LP, Dallas, TX) on subjects with mature, aging skin
 - The focus of this poster is on assessment of biomarkers
- Dermatoporosis is a condition of fragile, aging skin that is associated with both intrinsic and extrinsic factors along with the aging process.
- It is accompanied by alterations in supportive dermal structures, decreases in the ground substance of the extracellular matrix, and increased vulnerability of blood vessels to damage
- Dermatoporosis can subsequently manifest into wrinkles, skin laxity, easy bruising, and fragile skin

Elastin




Other Biomarkers

- There were trends in improvement in Beta Galactosidase (significantly increased in 4/5 subjects), and CD44 (significantly increased in 3/5 subjects)
- Beta Galactosidase is a widely accepted biomarker for assessment of cell senescence while CD44 is a skin receptor for hyaluronic acid

METHODS

- This was a 12-week multi-center, randomized, blinded, in-use study on female and male subjects of all races, ethnicities, and Fitzpatrick skin type aged 40-60 years, with GC applied twice daily
- Subjects were required to have a history of skin fragility and to be prone to bruising
 - Inclusion criteria also included dry, crepey skin on the knees
- Change from baseline to week 12 in protein expression was assessed by immunohistochemistry of clinical biopsy samples
 - A pinch test was used to assess knee skin elasticity at baseline and weeks 4, 8 and 12
- Digital photography was performed for clinical assessment

RESULTS



SUMMARY

- Twice daily use of this novel cream resulted in a notable, beneficial differences in the amount of important protein markers within the skin
- Specifically, elastin was significantly increased and there were trends in Beta Galactosidase and CD44
- This data will provide significant insights into the additional benefits of this cream for mature, aging, skin
- Additional study with a larger patient population is needed to confirm the Beta Galactosidase and CD44 trends

Disclosures:

Both Dr. Ablon and Dr. Schlesinger have served as investigators and consultants for Galderma. The remaining authors are employees of Galderma Laboratories, L.P.